DE60017194D1 - Verfahren zur herstellung von carbapenem-antibiotika zubereitungen - Google Patents

Verfahren zur herstellung von carbapenem-antibiotika zubereitungen

Info

Publication number
DE60017194D1
DE60017194D1 DE60017194T DE60017194T DE60017194D1 DE 60017194 D1 DE60017194 D1 DE 60017194D1 DE 60017194 T DE60017194 T DE 60017194T DE 60017194 T DE60017194 T DE 60017194T DE 60017194 D1 DE60017194 D1 DE 60017194D1
Authority
DE
Germany
Prior art keywords
carbapenem
preparing
carbapenem antibiotic
antibiotic preparations
preparing carbapenem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017194T
Other languages
English (en)
Other versions
DE60017194T2 (de
Inventor
Anthony Al-Dehneh
A Hunke
J Illig
Anand Kanike
Hiren Patel
D Reynolds
C Tsinontides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE60017194D1 publication Critical patent/DE60017194D1/de
Application granted granted Critical
Publication of DE60017194T2 publication Critical patent/DE60017194T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
DE60017194T 1999-10-29 2000-10-27 Verfahren zur herstellung von carbapenem-antibiotika zubereitungen Expired - Lifetime DE60017194T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16248299P 1999-10-29 1999-10-29
US162482P 1999-10-29
PCT/US2000/029869 WO2001032172A1 (en) 1999-10-29 2000-10-27 Process for formulation of carbapenem antibiotic compositions

Publications (2)

Publication Number Publication Date
DE60017194D1 true DE60017194D1 (de) 2005-02-03
DE60017194T2 DE60017194T2 (de) 2005-12-22

Family

ID=22585803

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017194T Expired - Lifetime DE60017194T2 (de) 1999-10-29 2000-10-27 Verfahren zur herstellung von carbapenem-antibiotika zubereitungen

Country Status (8)

Country Link
EP (1) EP1244444B1 (de)
JP (1) JP4854899B2 (de)
AT (1) ATE285770T1 (de)
AU (1) AU770165B2 (de)
CA (1) CA2388163C (de)
DE (1) DE60017194T2 (de)
ES (1) ES2234689T3 (de)
WO (1) WO2001032172A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548492B1 (en) * 1999-10-29 2003-04-15 Merck & Co., Inc. Process for formulation of carbapenem antibiotic compositions
JP2005522422A (ja) * 2002-02-01 2005-07-28 シモダ、バイオテック（プロプライエタリー）リミテッド 医薬組成物
EP2505190A1 (de) * 2008-06-11 2012-10-03 Ranbaxy Laboratories Limited Polymorphe Form eines Ertapenem-Mononatriums und dessen Herstellungsprozess
US8691803B2 (en) 2011-01-24 2014-04-08 Savior Lifetec Corporation Process for the preparation of antibiotic compounds
CA2910421A1 (en) 2013-05-07 2014-11-13 Mcmaster University Inhibitors of metallo-.beta.-lactamase-enzymes
KR101587420B1 (ko) * 2014-08-20 2016-01-22 주식회사 대웅제약 에르타페넴-함유 동결건조제제의 제조방법
KR20170014842A (ko) 2015-07-31 2017-02-08 주식회사 대웅제약 개선된 에르타페넴 주사제의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA62920C2 (en) * 1996-05-28 2004-01-15 Merck & Co Inc Carbapeneme antibiotic, a composition and a method for the preparation
HRP970281B1 (en) * 1996-05-28 2002-04-30 Merck & Co Inc Carbapenem antibiotic, composition and method of preparation
AU725298B2 (en) * 1996-10-28 2000-10-12 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
DE69819727T2 (de) * 1997-06-16 2004-09-23 Merck & Co., Inc. Stabilisierte carbapenem-zwischenprodukteund ihre verwendung in der synthese

Also Published As

Publication number Publication date
AU770165B2 (en) 2004-02-12
AU1245601A (en) 2001-05-14
ES2234689T3 (es) 2005-07-01
CA2388163A1 (en) 2001-05-10
JP2003514779A (ja) 2003-04-22
WO2001032172A1 (en) 2001-05-10
EP1244444A1 (de) 2002-10-02
JP4854899B2 (ja) 2012-01-18
CA2388163C (en) 2009-08-25
EP1244444B1 (de) 2004-12-29
EP1244444A4 (de) 2003-05-21
ATE285770T1 (de) 2005-01-15
DE60017194T2 (de) 2005-12-22

Similar Documents

Publication Publication Date Title
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
BR0207294A (pt) Composto, processo para a preparação de um composto ou de um sal farmaceuticamente aceitável ou um éster hidrolisável in vivo dos mesmos, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável ou um éster hidrolisável in vivo dos mesmos, e, método para a produção de um efeito inibitório do ciclo celular (antiproliferação celular) em um animal de sangue quente
CA2030433A1 (en) New isoquinoline- carboxamide amino acid derivatives useful for treatment of viral diseases
ATE378341T1 (de) Verfahren zur formulierung antibiotischer verbindungen
PT790974E (pt) Acidos 4-biarilbutiricos ou 5-biarilpentanoicos substituidos e seus derivados como inibidores de metaloproteinas de matriz
EP0649655A1 (de) Injektionslösungen enthaltend anti-ulcer Benzimidazole und Amide
FI951468A0 (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
HU9201258D0 (en) Process for the production of medical preparations for treating hiv infections and of their active agents
NO159592C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolidinderivater.
KR910015562A (ko) 뇌부전 질환치료용 약제, 신규 2-(1-피페라지닐)-4-페닐시클로알카노 피리미딘 유도체, 및 그의 제법
FI882605A (fi) Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta
ES2132135T3 (es) Procedimiento para la preparacion de compuestos de tiazolidina u oxazolidina farmaceuticamente activos mediante una reductasa de levadura.
DE60017194D1 (de) Verfahren zur herstellung von carbapenem-antibiotika zubereitungen
AU636653B2 (en) Stabilized leukocyte-interferons
FI96424B (fi) Menetelmä kiteisten kefeemihappoadditiosuolojen valmistamiseksi
DE69019404D1 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
CN103432569B (zh) 重组人血清白蛋白-干扰素α融合蛋白的水溶液及其制备方法
AU1022688A (en) Antibacterial lyophilized preparation
EP0153710A2 (de) Aus Pseudomonas aeruginosa stammende Elastase-Toxoide
HUP9701744A1 (hu) 9(S)-Eritromicilamin 9-N-etenil származékai, ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE210985T1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 6 infektionen
RU94031260A (ru) Питательная среда для выделения и культивирования гонококка
JPS6399022A (ja) 静脈内投与に適したガンマ・グロプリン
UA28523A (uk) Спосіб пригнічення репродукції вірусу імунодефіциту людини

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US

8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1244444

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1244444

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213